Effect of azidothymidine (AZT) on HIV P24 antigen, beta2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS

Abstract

Circulating HIV P24 antigen, beta2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and TNF alpha levels were measured in 20 patients (9 with ARC and 11 with AIDS) treated with azidothymidine (AZT) and in 12 patients (3 with ARC and 9 with AIDS) who were in a placebo group. Mean levels of HIV P24 antigen, beta2-microglobulin, neopterin and SCD8 decreased significantly ( P<0.05) after 12 to 16 weeks of AZT administration. SIL-2R and TNF alpha serum levels did not appear to change in association with AZT therapy. No changes were observed in the placebo group except that TNF alpha levels appeared to increase after 12 to 16 weeks. These results suggest that AZT administration may have led to reduced HIV P24 antigen, beta2-microglobulin, neopterin and SCD8 mean levels in these patients.